Human Herpesvirus 6A (HHV‑6A) is a variant of human herpesvirus 6 that belongs to the Betaherpesvirinae subfamily. It is an enveloped double‑stranded DNA virus that infects T lymphocytes and other cell types and establishes latency by integrating into host chromosomes.
Biology and Unique Features
HHV‑6A has an icosahedral capsid, a dense tegument and a lipid envelope adorned with glycoprotein complexes that mediate cell entry. Like other betaherpesviruses, it has a large genome (~165 kb) encoding structural, regulatory and immunomodulatory proteins. HHV‑6A can enter cells through the receptor CD134 (OX40) and possibly other receptors, leading to fusion and delivery of the viral genome into the nucleus. Replication follows the typical herpesvirus cascade of immediate early, early and late gene expression and results in enlarged cells with intranuclear inclusions. A distinguishing feature is the ability of HHV‑6A to integrate its genome into the telomeric regions of human chromosomes, creating a latent state that can be inherited through the germ line (chromosomally integrated HHV‑6). Reactivation may occur in response to cellular stress or immunosuppression, with production of infectious particles. HHV‑6A is more neurotropic than the closely related HHV‑6B and can infect glial cells, but its full cellular tropism and replication kinetics are still being elucidated.
Potential Clinical Associations
Unlike HHV‑6B, which causes roseola infantum (exanthem subitum) in infants, HHV‑6A has no clearly defined disease in healthy individuals. It is ubiquitous in human populations, with seroprevalence varying by region. Studies have detected HHV‑6A DNA in brain tissue and have suggested associations with several neurological conditions, including multiple sclerosis, encephalitis and epilepsy, but causal roles remain unproven. In immunocompromised patients, especially transplant recipients, reactivation of chromosomally integrated or latent HHV‑6A can contribute to fever, bone marrow suppression, graft dysfunction and central nervous system disease. Diagnosis relies on polymerase chain reaction and distinguishing between latent integrated genome and active replication can be challenging. There is no approved vaccine or specific antiviral therapy; ganciclovir, foscarnet and cidofovir have activity against HHV‑6 but their effectiveness for HHV‑6A‑related disease is uncertain. Research continues to clarify the epidemiology and pathogenic potential of this virus. HHV‑6A is a human betaherpesvirus with remarkable genomic integration capability and possible neurotropic properties. Although it is widespread, its clinical significance remains less defined than that of HHV‑6B, warranting further investigation into its biology and potential disease associations. Related Terms: human herpesvirus 6B, roseola infantum, chromosomally integrated HHV‑6, betaherpesvirus, encephalitis